Meda announced today positive results from a Phase III clinical trial of Dymista (also known as MP29-02), a novel formulation of azelastine hydrochloride and fluticasone propionate, in patients with ...
This leaflet provides important information about using DYMISTA ALLERGY. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or ...
Meda presents new positive results from a Phase-III clinical trial of Dymista (also known as MP29-02) at the annual meeting of the European Academy of Allergy and Clinical Immunology (EAACI) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results